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Summ In order to determine the clinical features of hepatocellular carcinoma in the elderly. a total of 622
patients With hepatocellular carcinoma, including 91 patients 70 years or older, were retrospectively analysed
With reference to their ages at the time of diagnosis. The proportion of females increased and that of hepatitis
B surface antigen-positive cases decreased as age increased. Tumour sizes at the time of diagnosis were
somewhat smaller in the elderly than in younger patients. whereas clinical stage taking liver function into
consideration was similar in the two age groups. The prognosis in the elderly patients was similar to that in
the younger ones in a clinical stage-matched comparison. Furthermore, by a multivariate analysis using the
Cox proportional hazards model with inclusion of age and other clinical parameters. age was not selected in
the final model as an independent predictor for survival. These results indicate that elderly patients with
hepatocellular carcinoma have certain clinical features different from those in younger patients and that their
prognosis is not necessarily poorer than in the latter.
Hepatocellular carcinoma (HCC) is a major malignancy in
many countries. particularly in sub-Saharan Africa and the
Far East. Most HCC patients are between 40 and 60 years.
and the clincical features of this cancer have been extensively
studied (Okuda. 1976: Chlebowski et al.. 1984: Dunk et al..
1988). There have been several reports describing the clinical
profile of HCC in childhood and adolescence (Lack et al..
1983: Cheah et al.. 1990). Not much attention. however, has
been given to clinical aspects of this malignancy among the
elderly. Since the relative proportion of older persons is
increasing in many countries. it is necessary to clarify the
clinical characteristics of elderly HCC patients. During the 9
years up to 1986. we studied 91 patients with HCC who were
70 years or older and determined their clinical features and
prognosis in comparison with 531 younger patients.
Patients and methods
A total of 622 consecutive patients with unequivocal HCC.
including 91 elderly patients age 70 years or older who were
admitted to the First Department of Medicine. Chiba
University Hospital. and affiliated hospitals over a 9 year
period up to December 1986. were retrospectively analysed
with reference to their ages at the time of diagnosis. There
were 507 men and 115 women and their ages ranged from 18
to 85 years. The diagnosis was made histologically in 447
cases. and in others with relatively large tumours it was
based on serum a-fetoprotein (AFP) levels and or typical
angiographic findings. AFP and hepatitis B surface (HBs)
antigen were measured by radioimmunoassay. The size of the
primary tumour was evaluated by ultrasonography, com-
puterised tomography and angiography. Size was expressed
as the diameter for relatively small and solitary tumours; in
the remainder. the proportion of the sum of the tumour areas
relative to the whole liver area on the angiogram or com-
puterised tomogram was taken as the size of the tumour as
described previously (Nomura et al.. 1989). Five hundred
patients had liver cirrhosis. 275 patients had histological
evidence of cirrhosis, and in the remainder the diagnosis was
based on unequivocal clinical grounds (presence of oesopha-
geal varices at endoscopy and or collateral circulation at
echography) and laboratory data. The patients were classified
into Child's three grades (Child. 1964) based on their clinical
status on admission. Furthermore. stratification of the patients
was performed according to the staging system described by
Okuda et al. (1985):
Stage I (not advanced): tumour size less than 50%. no
ascites. albumin greater than 3 g dl
-' and bilirubin less
than 3 mg dl- '.
Stage II (moderately advanced): one or two of the signs
of advanced disease present.
Stage III (very advanced): three or all of the advanced
signs present.
Surgery. varying from partial resection or enucleation to
extended lobectomy, was carried out in 83 patients, trans-
catheter arterial embolisation using Gelfoam (Upjohn.
Kalamazoo. MI. USA) in 128. intra-arterial chemotherapy
using a bolus dose or microcapsular forms of mitomycin C
and or adriamycin (doxorubicin: Adria laboratories. Colom-
bus. OH. USA) in 166 and other therapeutic methods in 83.
No specific treatment was given in 162. who were treated
palliatively. Results are given as mean ± standard deviation.
Comparisons were made by the chi-square test with Yates'
correction. Survival rate was calculated from the time of
cancer diagnosis by the life table method, and statistical
analysis was performed using the generalised Wilcoxon test.
A multivariate analysis of prognostic variables including age,
gender. tumour size, bilirubin and albumin values, serum
AFP levels and Child's grades was performed. To assess the
relative prognostic importance of factors in predicting sur-
vival, the Cox proportional hazards regression was employed
using a stepwise procedure (Cox. 1972). Calculations were
done with the statistical package of SAS as outlined by
SUGI Supplemental Library User's Guide (SAS Institute,
Carey. NC. USA). P-values less than 0.05 were considered
significant.
Results
Age and sex distribution ofpatients
Figure 1 shows the age and sex distribution of the 622
patients. Of these, 91 or about 15% were 70 years or older.
The proportion of females gradually increased as age in-
creased: 4.5% in the <45 years group versus 31.8% in the
> 70 years group (P<0.02). Dunrng the same study period. a
total of 17,511 patients were admitted to the Department of
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Medicine in our hospital. Among them, the proportions of
females in the <45 years group and in the > 70 years group
were quite similar (43.9% vs 44.1%), in contrast to the case
with patients with HCC.
Clinical stage ofpatients and HBsAg prevalence
Demographic and clinical data on the three age groups of
patients are given in Table I. The prevalence of HBsAg-
positive cases and the proportion of large tumours (tumour
> 50% of the liver) was lowest in the elderly group, whereas
the distribution of the clinical stages proposed by Okuda was
similar among the three age groups. It is of note that HBsAg
was positive in nearly 70% of patients younger than 45 years.
During the same study period, we cared for a total of 215
patients with post-hepatitic liver cirrhosis in our own unit.
The average age of HBsAg-positive patients at the time of
diagnosis was significantly lower than that of HBsAg-
negative patients (46.8 ± 7.5 vs 52.0 ± 4.5, P<0.001).
Therapeutic modalities in HCC patients with various age
groups
Table II summarises the treatments given to patients with
HCC in relation to age. Patients aged 70 years or older were
more likely to be untreated and were significantly less likely
to receive surgery (4 91 vs 79 531. P<0.02).
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Table I Tumour sizes and clinical stages at the time
groups
of diagnosis in 622 HCC patients of various age
Age HBsAg (+) Twnour size (%) Clinical stage (%}
(Oears) n (%) < 5 cm 5 cm-50% > 50% I II III
<44 40 67.5 9 (22.5) 11 (27.5) 20 (50.0)* 28.2 46.1 25.7
45-69 491 19.1 175 (35.6) 163 (33.2) 153 (31.2) 36.0 48.6 15.4
>70 91 13.1** 33 (36.3) 38 (41.7) 20 (22.0) 35.2 52.7 12.1
*P <0.01 vs >45 years group; **P <0.01 vs <70 years group.
Table II Therapeutic modalities in 622 HCC patients of various ages (percentage in
parentheses)
Transcatheter
Age No. of Intra-arterial arterial
(Years} patients Surgery chemotherapy embolisation Others No treatment
<44 40 8 (20.0) 9 (22.5) 4 (10.0) 9 (22.5) 10 (25.0)
45-69 491 71 (14.5) 132 (26.9) 104 (21.2) 63 (12.8) 121 (24.6)
>70 91 4 (4.4)* 25 (27.4) 20 (22.0) 11 (12.1) 31 (34.)
*P <0.02 vs <70 years group.692 F. NOMURA et al.
Table m Multivanrate analysis of major prognostic factors by the
Cox proportional hazards model (variables selected in the final
model)
Variables Regression P-value
coefficient
Child's grade 0.64250613 <0.0001
Tumour size 0.35645823 <0.0001
AFP 0.00000108 <0.04
Total bilirubin 0.01762973 <0.05
Survival ofelderly patients with hepatocellular carcinoma
The median survival of 622 patients regardless of their ages
was 13.7 ± 16.8 months as of March 1992. Survival rates for
elderly ( 70 years) and non-elderly (<70 years) patients
were compared taking the chmlcal stage of the tumours into
consideration. As shown in Figure 2, there was no stati-
stically significant difference in survival rate between the two
age groups for each stage. Furthermore, stepwise Cox regres-
sion analysis of the main variables revealed that Child
grades, tumour size. total bilirubin and AFP level were sig-
nificant and independent predictors of survival (Table III),
but that age was not.
Discussion
Various forms of cancer may present different clinical
features in the elderly population (Huvos, 1986; Yancik et
al.. 1986, 1989; Teeter et al., 1987; Walker et al., 1990). In
the present study. we assessed the clinical features and sur-
vival rates in elderly HCC patients of 70 years of age or
older. Analysis of demographic features in these patients
revealed that HBsAg positivity was significantly less frequent
in elderly than in younger patients. Also, the proportion of
females gradually increased with increasing age. The exact
reasons for there being a greater proportion of females in the
elderly group are not clear, but we speculate that slower
progression of chronic viral hepatitis in females and lower
prevalence of heavy drinkers may partly account for this.
Stored sera were available for 164 non-A, non-B patients
of the present series, and anti-HCV measured by the second-
generation enzyme immunoassay (EIA-2, Ortho Diagnostics,
Ranitau, NJ, USA) was found in 92%; the age distribution
of those 164 patients was similar to that of all the patients
included in this study. It has been reported that the elderly
are more likely to present at initial diagnosis with advanced
stages in the case of ovarian cancer (Yancik et al., 1986),
breast cancer (Yancik et al., 1989) and Hodgkin's disease
(Walker et al., 1990). However, this was not the case with
HCC. Indeed, it was found that the diagnosis was made at a
less advanced stage in terms of the size of the tumour in the
elderly than in the younger patients (Table I). In Japan,
patients with liver cirrhosis are encouraged to have examina-
tions using a combination of real-time ultrasonography and
AFP measurement at regular intervals for an early detection
of HCC (Okuda, 1986). It is conceivable that the older HCC
patients are, the more definite the diagnosis of liver cirrhosis,
and as a result they are more likely to undergo such
examinations, which, in turn, may lead to early detection of
HCC. Increasing age has frequently been reported to have a
negative impact on the survival of patients with several types
of cancer, such as ovarian cancer (Yancik et al., 1986), breast
cancer (Yancik et al., 1989) and Hodgkin's disease (Walker et
al.. 1990). Again, this was not found to be the case with
HCC in this study. The prognosis of the elderly HCC
patients was found to be similar to that for the younger cases
as assessed by two different analyses. In a stage-matched
comparison of elderly and non-elderly patients, the prognosis
of the former was not statistically different from that of the
latter. Furthermore. in a multivariate analysis using the Cox
proportional hazards model age was not selected as an
independent negative predictor of survival. The multivariate
analyses were also carried out separately in three groups of
patients treated by three different modalities (surgery. intra-
arterial chemotherapy and TAE), and in each case age was
not selected as a significant predictor (data not shown). This
observation that old age is not a significant negative predic-
tor of survival in HCC patients is at variance with the
findings of other studies (involving relatively small numbers of
patients) that suggested advanced age to be associated with a
shorter survival in HCC (Chlebowski et al.. 1984; Falkson et
al., 1988; Calvet et al.. 1990; Okada et al., 1992). The exact
reason for this discrepancy is not clear, but the difference
may be explained in part by the prevalence of advanced
cases. Indeed, in those previous studies, the majority of
patients, most of whom had systemic chemotherapy. had
very advanced disease and their median survivals ranged
from only 3.3 to 5.6 months. By contrast, the median sur-
vival was 13.7 months in this study. Differences in ethnic
background of HCC patients might also account for the
differences in survival. The current finding obtained with a
large number of patients that old age is not necessarily a
negative predictor of survival may be encouraging from a
therapeutic point of view. Elderly patients were significantly
less likely to undergo surgery (Table II), which is in accor-
dance with a general view that advanced age has an adverse
effect on the safe limit of surgical resection. However, per-
cutaneous ethanol injection therapy (Sugiura et al.. 1983;
Castells et al., 1993), which is definitely less invasive than
surgery, is increasingly being carried out and so elderly HCC
patients may soon have a better survival with somewhat imp-
roved prognostic outcome.
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